Clinical Insights & Research

Skimping on Sleep Leads to Weight Gain
Clinical Studies & Findings

Skimping on Sleep Leads to Weight Gain

People who shortened their sleep by around 80 minutes a night for six weeks gained weight—one pound on average—and were more sedentary, researchers at Columbia University Vagelos College of Physicians and Surgeons have found. “Our study shows that getting adequate sleep may help reduce the risk of weight gain and obesity-related […]

TAP Sleep Care Publishes myTAP Case Study Showing Rapid OSA Improvement
Dental Sleep Medicine

TAP Sleep Care Publishes myTAP Case Study Showing Rapid OSA Improvement

TAP Sleep Care® announced the publication of a compelling case report demonstrating the rapid, near-complete effectiveness of its myTAP® chairside titratable oral appliance when combined with a mouth shield for nasal breathing. Case #13 titled, “Two-Night Breakthrough in Treatment-Resistant OSA: Immediate-Effective Outcomes by combining Chairside OA with Mouth Shield,” authored […]

Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Clinical Studies & Findings

Addex Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness

Addex Therapeutics announced publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 7 (mGlu7), significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models. The data, published in the International Journal of Neuropsychopharmacology, expands the growing body of evidence supporting mGlu7 […]

LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
Clinical Insights & Research Sleep Apnea

LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study

Recently published study results demonstrate the efficacy of LivaNova Plc’s aura6000 System in treating moderate to severe obstructive sleep apnea (OSA). Published in Annals of Internal Medicine, the full 12-month results from the company’s OSPREY randomized controlled trial (RCT) demonstrate the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS), a differentiated neurostimulation modality. Overall, the study authors concluded that pHGNS for OSA yielded clinically significant improvements versus […]

ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options
Partnerships & Collaborations Sleep Pharmaceuticals

ŌURA and LillyDirect to Expand Support for People Using GLP-1 Therapies with New Tools and Savings Options

ŌURA maker of the world’s most trusted smart ring, Oura Ring, and LillyDirect, Eli Lilly and Company’s digital health platform designed to connect people living with chronic conditions to the care, support, and prescribed medicines they need, today announced a collaboration enabling savings on the Oura Ring sizing kit. The […]

prosomnus monitair
Dental Sleep Medicine Sleep Apnea Partnerships & Collaborations

ProSomnus and MonitAir Collaborate to Enhance Connected Care for OSA

ProSomnus Sleep Technologies (“ProSomnus”), pioneer of Smart Sleep Medicine™, and MonitAir, LLC (“MonitAir”), the premier digital health and tele-monitoring platform for sleep medicine announced a collaboration to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ […]

Jazz Pharmaceuticals to Present Data at SLEEP 2026 Highlighting Effects of Xywav for Narcolepsy and Idiopathic Hypersomnia
Sleep Pharmaceuticals

Jazz Delivers Extensive Data at SLEEP 2026, Real-World Impact of Xywav on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals plc delivered 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic […]

New Pivotal Study Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for Narcolepsy Type 1
Narcolepsy Sleep Pharmaceuticals

New Study: Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for Narcolepsy Type 1

New data presented by Takeda at SLEEP 2026 this week continues to build the case for oveporexton (TAK-861) as a potential disease-modifying treatment for narcolepsy type 1 (NT1). Oveporexton is designed to address the root cause of the disease, targeting the underlying orexin deficiency responsible for NT1. Results from two pivotal […]

Alkermes Presents Alixorexton and LUMRYZ Data at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Sleep Pharmaceuticals

Alkermes Presents Alixorexton and LUMRYZ Data at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]